CB Scientific Announces Addition of Brooke Martellaro as Chief Financial Officer
Back to Newsroom
Mentioned in this Article

CB Scientific Announces Addition of Brooke Martellaro as Chief Financial Officer

Tuesday, November 2, 2021 6:00 AM
Share this article now
Topic:
Company Update
CB Scientific, Inc.

Seasoned finance executive and business leader to add significant incremental competencies to the Company's executive management team

ESCONDIDO, CA / ACCESSWIRE / November 2, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") is a provider of remote ECG cardiac monitoring products and services; simple wearable solutions for detecting potentially life-threatening heart arrhythmias in patients with heart-related issues, both domestically and internationally.

The Company has announced that Brooke Martellaro has been appointed as its Chief Financial Officer effective immediately. Ms. Martellaro began her career with Arthur Andersen & Co. before progressing quickly to positions of ever-increasing responsibility with Jones Intercable, Qwest Communications International, and Dex Media, a $1.6 Billion, NYSE-listed private equity portfolio company, and others. Since launching her independent consulting practice, Ms. Martellaro has advised clients in the Construction, Financial, Healthcare, Industrials, Professional Services, Real Estate, and Technology sectors on strategic, financial, and operational improvements.

"We feel quite fortunate to have attracted a talented senior financial executive with such exceptional professional credentials," said Charles Martin, Chief Executive Officer of CB Scientific. "Her deep working knowledge and extensive experience in the areas of budgeting, forecasting, business planning, strategic communication, financial strategy, regulatory compliance, and SEC reporting is truly remarkable, and we expect it will add significant tangible value to our leadership team, now and in the future."

The Company's immediate plan for Ms. Martellaro is to fully engage with MaloneBailey LLP as they work to conclude a Public Company Accounting Oversight Board (PCAOB) audit, which will be included in an annual report to be filed with OTC Markets, a critical next step for CBSC to advance to the OTCQB Venture Market in the very near future.

"I am looking forward with great enthusiasm to immersing myself in the Company's operations in order to come up to full speed as rapidly as possible," said Brooke Martellaro, newly appointed Chief Financial Officer of CBSC. "I believe this opportunity provides a perfect venue for me to make a positive impact by applying my expertise to implement short-term improvements and help better position us for long-term success."

An accomplished financial leader and author, Ms. Martellaro earned a Master of Science degree in Business Administration from Colorado State University and a Bachelor of Arts degree in Organizational Communication from Western Colorado University. She is a Certified Public Accountant, board member, and volunteer and is a Dale Carnegie and PSI Seminars Women's Leadership graduate.

As additional new developments occur, CB Scientific plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

About CB Scientific, Inc.

CB Scientific, Inc. (https://cbscientificinc.com/), through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: [email protected]
Investor Inquiries: Robert Hesse - [email protected]
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE: CB Scientific, Inc.

Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions